Absent 'Gold Standard' for HER2 Testing, Researchers Question Role of Oncotype DX Beyond IHC/FISH
December 21, 2011
Absent 'Gold Standard' for HER2 Testing, Researchers Question Role of Oncotype DX Beyond IHC/FISH
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- MDx/CDx Focus: Positive Data for Trastuzumab Emtansine; Veracyte Gets NY OK for Afirma Thyroid Dx
August 29, 2012 / Pharmacogenomics Reporter - FDA Speeds New HER2-Targeted Drug and Companion Tests to Market
June 13, 2012 / Pharmacogenomics Reporter - Oncotype DX Study Raises Questions About RT-PCR Testing for HER2 Expression
December 1, 2011 / PCR Insider - Genentech, Dako Submit Applications to FDA for Herceptin in HER2-Positive Stomach Cancer
June 2, 2010 / Pharmacogenomics Reporter - FDA Approves Genentech's Antibody-Drug Conjugate, Marking Third Rx for HER2-Targeted Breast Cancer
February 27, 2013 / Pharmacogenomics Reporter